Company / Operating Cash Flow per Share
Spyre Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.81
FY2025
5-year range
-$38.22 / -$1.12
FY2021-FY2025
Trend
+35.7%
vs FY2024
Sector context
#164 of 212
Health Care
What the data says
Spyre Therapeutics, Inc.'s operating cash flow per share of $-2.81 is lower than 77% of companies in the Health Care sector (FY2025). Improved from $-38.22 to $-2.81 over the past 2 years.
Based on SEC 10-K filings.
-2.81 in FY2025.
Improved from $-38.22 to $-2.81 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 212This company -$2.81 Sector average -$14.72
▼
+80.9% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 35.7% year-over-year.
- Ranks #164 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2019.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.81 | +35.7% |
| FY2024 | -$4.37 | +88.6% |
| FY2023 | -$38.22 | -2389.5% |
| FY2022 | -$1.54 | -37.1% |
| FY2021 | -$1.12 | -1.2% |
| FY2020 | -$1.11 | -8.6% |
| FY2019 | -$1.02 | +9.8% |
| FY2018 | -$1.13 | +30.5% |
| FY2017 | -$1.63 | +15.4% |
| FY2016 | -$1.92 | +89.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026